Immunization with the Haemophilus ducreyi Hemoglobin Receptor HgbA with Adjuvant Monophosphoryl Lipid A Protects Swine from a Homologous but Not a Heterologous Challenge by Fusco, W. G. et al.
INFECTION AND IMMUNITY, Sept. 2010, p. 3763–3772 Vol. 78, No. 9
0019-9567/10/$12.00 doi:10.1128/IAI.00217-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Immunization with the Haemophilus ducreyi Hemoglobin Receptor
HgbA with Adjuvant Monophosphoryl Lipid A Protects Swine
from a Homologous but Not a Heterologous Challenge
William G. Fusco,1 Galyna Afonina,1† Igor Nepluev,1† Deborah M. Cholon,1 Neelima Choudhary,1
Patricia A. Routh,3 Glenn W. Almond,3 Paul E. Orndorff,3 Herman Staats,4
Marcia M. Hobbs,1,2 Isabelle Leduc,1* and Christopher Elkins1,2
Division of Infectious Diseases, Departments of Medicine1 and Microbiology and Immunology,2 University of North Carolina,
Chapel Hill, North Carolina 27599; College of Veterinary Medicine, North Carolina State University, Raleigh,
North Carolina 276063; and Department of Pathology, Duke University Medical Center,
Durham, North Carolina 277104
Received 4 March 2010/Returned for modification 19 March 2010/Accepted 18 June 2010
Haemophilus ducreyi, the etiological agent of chancroid, has a strict requirement for heme, which it acquires
from its only natural host, humans. Previously, we showed that a vaccine preparation containing the native
hemoglobin receptor HgbA purified from H. ducreyi class I strain 35000HP (nHgbAI) and administered with
Freund’s adjuvant provided complete protection against a homologous challenge. In the current study, we
investigated whether nHgbAI dispensed with monophosphoryl lipid A (MPL), an adjuvant approved for use in
humans, offered protection against a challenge with H. ducreyi strain 35000HP expressing either class I or class
II HgbA (35000HPhgbAI and 35000HPhgbAII, respectively). Pigs immunized with the nHgbAI/MPL vaccine
were protected against a challenge from homologous H. ducreyi strain 35000HPhgbAI but not heterologous
strain 35000HPhgbAII, as evidenced by the isolation of only strain 35000HPhgbAII from nHgbAI-immunized
pigs. Furthermore, histological analysis of the lesions showed striking differences between mock-immunized
and nHgbAI-immunized animals challenged with strains 35000HPhgbAI but not those challenged with strain
35000HPhgbAII. Mock-immunized pigs were not protected from a challenge by either strain. The enzyme-linked
immunosorbent assay (ELISA) activity of the nHgbAI/MPL antiserum was lower than the activity of antiserum
from animals immunized with the nHgbAI/Freund’s vaccine; however, anti-nHgbAI from both studies bound
whole cells of 35000HPhgbAI better than 35000HPhgbAII and partially blocked hemoglobin binding to nHgbAI.
In conclusion, despite eliciting lower antibody ELISA activity than the nHgbAI/Freund’s, the nHgbAI/MPL
vaccine provided protection against a challenge with homologous but not heterologous H. ducreyi, suggesting
that a bivalent HgbA vaccine may be needed.
Chancroid is one of the genital ulcer diseases and is trans-
mitted through sexual contact. Lesions caused by chancroid
initially appear as papules, which evolve within several days
into pustules. If left untreated, chancroid pustules develop into
painful, bleeding ulcers with soft, irregular borders. Chancroid
is prevalent in certain developing countries but is rarely found
in the United States (47, 62). Several studies have shown that
chancroid serves as an important independent cofactor in the
heterosexual transmission of HIV where both diseases are
endemic (29, 35, 48, 51, 66). Commercial sex workers serve as
the reservoir of chancroid, and control of disease in this pop-
ulation strikingly reduces the number of cases of chancroid in
their male clients (58). Thus, one possible approach to control
chancroid is to implement a limited vaccination program to
control infection in this reservoir; however, no vaccine for
chancroid currently exists.
Haemophilus ducreyi, the etiologic agent of chancroid, is a
fastidious Gram-negative bacterium and a strict human patho-
gen. An interesting biologic feature of H. ducreyi is its obligate
requirement for heme. Heme (for H. ducreyi) and iron are
critical nutrients required for most pathogenic bacteria. Many
Gram-negative bacteria obtain heme/Fe through systems that
include TonB-dependent outer membrane receptors specific
for heme/Fe compounds. The relatively small genome of pro-
totypical H. ducreyi strain 35000HP encodes only three TonB-
dependent receptors; in comparison, other bacterial genomes
can encode more than 30 (14). Using isogenic mutants, the
Spinola and Elkins laboratories surveyed the ability of H. ducreyi
TonB-dependent receptor mutants to initiate infection in the
human experimental model of chancroid. An H. ducreyi mutant
that does not express the gene encoding the hemoglobin (Hb)
receptor, hgbA, did not establish human infection (3). In contrast,
an isogenic double mutant lacking the genes encoding the two
other TonB-dependent receptors of H. ducreyi, tdhA and tdX, was
fully virulent, indicating that HgbA is the only TonB-dependent
receptor of H. ducreyi to be a virulence factor in the human
experimental model of chancroid (38). Since HgbA is required for
the utilization of heme from Hb by H. ducreyi (17), these data
suggest that Hb is the most important source of heme in the early
stages of the human experimental model of chancroid and that
HgbA is a potential vaccine candidate.
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HgbA is a large, 100-kDa outer membrane protein that has
a complex structure similar to that of other TonB-dependent
receptors whose structure has been solved (10, 12, 20, 21, 40).
HgbA is believed to contain 22 transmembrane beta sheets and
11 putatively surface-exposed loops. A recent study in our
laboratory using H. ducreyi mutants expressing single loop de-
letions in HgbA provided evidence for surface exposure of
loops 4, 5, 6, and 7 (44). Moreover, deletions of loops 5 and 7
but not of the other 9 loops of HgbA abrogated the binding of
human Hb to HgbA. We also found that IgG from pigs immu-
nized with native HgbA (nHgbA) bound loops 4, 5, and 7 and
that antibodies directed at loops 4 and 5 partially blocked Hb
binding to HgbA in vitro. Thus, a central domain of the primary
sequence of HgbA is immunogenic, required for binding Hb,
and surface exposed.
H. ducreyi strains exist in two groups, designated class I and
class II, based on striking primary sequence differences in
certain outer membrane proteins, such as DsrA (ducreyi serum
resistance A) and NcaA (necessary for collagen adhesion A),
and on their lipooligosaccharide (LOS) structures (49, 50, 53,
67). In contrast, the HgbA proteins of different classes of H.
ducreyi strains are more than 95% identical. Prototypical H.
ducreyi strain 35000HP, a class I isolate, is the strain used for
most studies, including isogenic mutant construction and the
experimental human model of chancroid. 35000HP is the only
H. ducreyi strain whose genome has been sequenced.
Previously, we showed that immunization of swine with na-
tive HgbA from class I strain 35000HP (nHgbAI) in Freund’s
adjuvant provided complete protection from a homologous
challenge infection with H. ducreyi strain 35000HP (1). The
antibodies elicited by nHgbAI/Freund’s showed modest bacte-
ricidal activity, bound to the cell surface of both class I and
class II H. ducreyi strains, and partially blocked Hb binding to
nHgbA (1). nHgbAI antisera did not recognize the surface of,
nor did they show bactericidal activity against the isogenic
hgbA mutant, demonstrating specificity of the humoral re-
sponse to HgbA.
In the current study, we pursued two objectives. First, we
investigated the effectiveness of monophosphoryl lipid A
(MPL), an adjuvant approved for use in humans, to elicit an
immune response to the nHgbAI vaccine that is protective
against an H. ducreyi challenge in the experimental swine
model of chancroid. Second, we examined the ability of this
vaccine to protect swine from a challenge infection with H. ducreyi
strain 35000HP expressing either class I hgbA (hgbAI) or class II
hgbA (hgbAII) from H. ducreyi strain DMC111 (homologous ver-
sus heterologous challenge, respectively).
MATERIALS AND METHODS
Bacterial strains and growth conditions. H. ducreyi strain 35000HP (human-
passaged variant, class I strain) (4, 25) used in this study was obtained from
Stanley Spinola, Indiana University, Indianapolis, IN. H. ducreyi class II strain
DMC111 is an isolate from Bangladesh (67). The construction of isogenic hgbAI
mutant H. ducreyi strain FX547 was previously described (44). FX547 contains a
complete deletion of the hgbAI open reading frame, replaced with a chloram-
phenicol resistance cassette insert, and cannot grow on Hb plates (100 g/ml) as
a sole source of heme (44). For routine growth, H. ducreyi strains were main-
tained on chocolate agar plates containing gonococcal medium base (GCB;
Difco, Detroit, MI) and 1% bovine Hb (Becton Dickinson, Sparks, MD) and
supplemented with 1% GGC (0.1% glucose, 0.001% glutamine, 0.026% cysteine)
and 5% Fetalplex (Gemini Bio-Products, West Sacramento, CA). Cultures were
incubated at 34.5°C with 5% CO2.
Construction of H. ducreyi strain 35000HP expressing the hgbAII gene from
strain DMC111. A class I H. ducreyi strain expressing the class II hgbA gene
(hgbAII), 35000HPhgbAII, was constructed in the following fashion: PCR was
used to amplify hgbAII from H. ducreyi strain DMC111 using class II-specific
hgbA primers that contain restriction sites (underlined) (5-TAACACTTAAGG
AATACGTAATGAAAACGAATAAACTC-3 and 5-GAGAAATCATATGA
CAAAAAAGGGCACCGAAGT-3) and cloned into the AflII and NdeI sites of
pUNCH1411 (44) to create pUNCH1413. pUNCH1413 contains the open read-
ing frame of class II hgbA with class I hgbA flanking sequences. pUNCH1413
DNA was digested with EcoRI and XhoI, and the hgbA fragment isolated. This
DNA fragment was electroporated into H. ducreyi FX547, and cells plated on Hb
agar plates. Transformants that grew on Hb as a sole source of heme were
screened for the expression of HgbA by Western blotting. A single colony was
chosen, isolated, and sequenced. Two mutations were detected during sequenc-
ing. The first mutation was silent and the second mutation changed amino acid
21 of the mature protein from valine to glutamic acid. This change is in the
“plug” region of mature HgbA and is thought not to be surface exposed. The
HgbAII protein functions normally for growth on medium with Hb as the sole
heme source in 35000HP, and H. ducreyi strain 35000HPhgbAII is fully virulent in the
swine model. For the purpose of this report, wild-type H. ducreyi strain 35000HP will
be referred to as 35000HPhgbAI. To ensure that HgbAII was expressed at the same
level as HgbAI in the 35000HP background, outer membrane proteins were pre-
pared from low-heme liquid cultures of strains 35000hgbAI, 35000HPhgbAII, and the
hgbA isogenic null mutant 35000HPhgbA and subjected to SDS-PAGE followed by
Coomassie staining. HgbAII is expressed at a level similar to that of HgbAI in the
35000HP background in both whole cells and outer membrane protein preparations
(data not shown).
HgbA purification. Purification of nHgbAI and nHgbAII from H. ducreyi
strains 35000HPhgbAI and 35000HPhgbAII was performed as previously de-
scribed (1). The purity of both nHgbAI and nHgbAII was greater than 95% (data
not shown).
Animals. Eight Yorkshire Cross pigs were used in two separate immunization
experiments (four pigs per experiment). Pigs were obtained at 3 weeks of age and
housed at ambient temperature (20° to 25°C) in individual pens at the North
Carolina State University (NCSU) School of Veterinary Medicine. Pigs were
given water and antibiotic-free high-protein feed ad libitum starting 6 weeks prior
to the start of and continuing throughout the study. During inoculation and
biopsy procedures, pigs were sedated with 2 mg of ketamine HCl (Fort Dodge
Laboratories, Fort Dodge, IA) and 2 mg of xylazine (Miles Laboratories, Shaw-
nee Mission, KS) per kg of body weight, injected intramuscularly. Pigs at chal-
lenge generally weighed between 70 and 100 lbs. The Institutional Animal Care
and Use Committee (IACUC) at NCSU approved the use of animals for these
experiments.
Immunization protocol. The immunization protocol used in this study was
exactly replicated from the original nHgbAI vaccine trial so that the results from
the current study would be directly comparable to the one from the previous
study (1). In each of 2 experiments, 2 pigs were mock immunized with buffer (1%
octylglucoside [Calbiochem, La Jolla, CA] in phosphate-buffered saline [PBS])
and adjuvant alone and 2 pigs received nHgbAI in buffer and adjuvant. The MPL
adjuvant (Sigma, St. Louis, MO) was prepared according to the manufacturer’s
instructions. The immunogen was prepared by mixing 250 g of nHgbAI in 500
l PBS containing 1% octylglucoside with 500 l of MPL adjuvant. Each pig
received three intramuscular injections in the nuchal region in two sites 21 days
apart. Pigs were bled prior to each of the three immunizations, as well as before
challenge and biopsies. Pigs were euthanized immediately following biopsies in
accordance with IACUC protocols.
Challenge infection. Challenge infection was performed 21 days after the third
immunization. H. ducreyi strains 35000HPhgbAI and 35000HPhgbAII were grown
overnight at 34.5°C and 5% CO2 on chocolate agar plates supplemented with 1%
GGC and 5% FetalPlex. For each strain, a cell suspension at an optical density
at 600 nm (OD600) of 1.5 (approximately 1  109 CFU/ml) was prepared in GC
broth, along with a 1:10 dilution (approximately 1  108 CFU/ml). Multi-Test
skin test applicators (Lincoln Diagnostics, Decatur, IL) were used to inoculate 10
l of each bacterial suspension at multiple sites on the pig ears. Since the
efficiency of dose delivery by the Multi-Test skin test applicator has been esti-
mated at 1:1,000, 10 l of a 109 CFU/ml bacterial suspension delivers approxi-
mately 104 CFU, and 10 l of a 108 CFU/ml bacterial suspension delivers an
estimated 103 CFU dose (55). Prior to inoculation, the ears of the pigs were
cleaned thoroughly with alcohol wipes and lesion sites were marked with an ethanol-
resistant pen. Each pig was inoculated with H. ducreyi strain 35000HPhgbAI on the
left ear and strain 35000HPhgbAII on the right ear. The viability of bacterial
suspensions was determined prior to and after each experiment, and no decrease
in CFU was observed.
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Biopsy processing. Pig ear lesions were biopsied 1 week after infection using
disposable 6-mm skin biopsy punches (Acuderm, Ft. Lauderdale, FL). Biopsied
tissues were either placed in 0.5 ml of GC broth for bacterial recovery or in 0.5
ml of 4% paraformaldehyde for histological studies. In order to recover H.
ducreyi from biopsied lesions, tissues were thoroughly minced in GC broth using
a sterile scalpel and spread on chocolate agar plates supplemented with 1%
GGC, 5% FetalPlex, and 3 g/ml vancomycin to reduce contaminants (1). Plates
were incubated at 34.5°C with 5% CO2 for up to 72 h, the presence/absence of
H. ducreyi colonies was noted, and representative colonies were subcultured for
confirmatory PCR.
Sections of biopsy specimens preserved in 4% paraformaldehyde were stained
with hematoxylin and eosin (H&E) (Histology Laboratory, College of Veterinary
Medicine, North Carolina State University). Each slide was coded and graded
blindly by 2 authors according to a previously described protocol (1, 52). The
appearance of normal skin received a score of 1; the presence of perivascular and
interstitial mononuclear cell infiltrate received a score of 2; the presence of an
intraepidermal pustule with neutrophils, fibrin, and necrotic debris received a
score of 3; the presence of an epidermal pustule with keratinocyte cytopathology
and mononuclear and polymorphonuclear infiltrate received a score of 4; and
ulceration or epidermal necrosis and dermal erosion with confluence of immune
cells was scored a 5. All slides were viewed using a Leica DM IRB inverted
microscope (Leica Microsystems, Bannockburn, IL), and images were saved
using QCapture software (QImaging, Surrey, BC, Canada). The scores were
compared using Cohen’s kappa, which indicated that the similarity between the
evaluators (  0.541) was in moderate agreement.
ELISA. Enzyme-linked immunosorbent assays (ELISAs) were performed as
previously described (1), except that plates were coated with 100 ng/well of
nHgbAI instead of 200 ng/well. Each sample was run in duplicate, and the assay
was performed on at least 3 different days.
Hb-blocking ELISA. An ELISA was used to determine the ability of anti-
HgbAI to block Hb binding to HgbA (1). One hundred nanograms of nHgbAI or
nHgbAII in 0.1 M carbonate buffer (pH 9.5) was added to wells and incubated
overnight at 4°C. The next morning, wells were blocked for 1 h with 2% bovine
serum albumin (BSA)-PBS. Twenty micrograms of anti-nHgbAI IgG was added
to wells before a 30-min incubation at room temperature. Digoxigenin (DIG)-
labeled human Hb (400 ng in 1% BSA-PBS) was added to wells, and plates were
incubated at room temperature for 1 h. Three washes with PBS–0.05% Tween 20
(PBS-T) were followed by the addition of alkaline phosphatase-conjugated anti-
DIG antibodies (100 l, 1:5,000 in PBS) (Roche Diagnostics, Indianapolis, IN).
The plates were incubated for 1 h at room temperature and washed thrice with
PBS-T. One hundred microliters of alkaline phosphatase substrate (1-Step PNPP
[p-nitrophenyl phosphate]) (Pierce, Rockford, IL) was added to wells, and the
optical density at 405 nm was measured after 45 min using a 1420 VICTOR2
multilabel counter (Wallac Oy). The Hb was labeled with DIG according to the
manufacturer’s instructions (DIG protein labeling kit; Roche Diagnostics, Indianap-
olis, IN). IgG was purified from pig antisera using protein A/G resin according to the
manufacturer’s instructions (ExAlpha Biologicals, Watertown, MA).
Whole-cell binding ELISA. H. ducreyi strains 35000HPhgbAI and 35000HPhgbAII,
isogenic hgbAI mutant FX547, and H. ducreyi class II strain DMC111 were grown
overnight at 34.5°C with 5% CO2 and shaking for 15 h in GC broth supplemented
with 1% GGC and 5% Fetalplex. The whole-cell binding ELISA was performed as
previously described (1) with the following changes: two hundred microliters of each
strain of H. ducreyi (OD600  0.2) was added in triplicate to a Multiscreen HTS
96-well plate (Millipore, Billerica, MA). Fifty microliters of anti-nHgbA antisera was
added to wells (final dilution 1:2,000 in 0.25% Tween 20-GC broth) and incubated
for 90 min at room temperature with gentle rocking. Wells were washed 4 times with
0.1% Tween 20-GC broth using a vacuum manifold. One hundred microliters of
rabbit anti-pig IgG-horseradish peroxidase (HRP) (product no. A5670; Sigma, St.
Louis, MO), diluted 1:20,000 in 0.25% Tween 20-GC broth, was added to wells, and
the plate incubated at room temperature for 60 min with gentle rocking. Wells
were washed 4 times with 0.1% Tween 20-GC broth, and 100 l of HRP
substrate (Amersham ECL; GE Healthcare, Buckinghamshire, United King-
dom) was added to wells. Chemiluminescence was detected using the Wallac
1420 VICTOR2 plate reader.
Bactericidal assay. In order to determine the bactericidal activity of the
nHgbAI antisera against H. ducreyi strains, an immune bactericidal assay was
performed as previously described (1, 18). Percent killing was determined by
dividing the number of colonies that survived in fresh normal human serum
(NHS) by the number of colonies that survived in heat-treated NHS and multi-
plying by 100. There was no decrease in CFU for the heated NHS control
compared to the count in the GC broth control.
PCR amplification of loop 4 of the hgbA gene. To confirm strain identity, H.
ducreyi colonies obtained from biopsy specimens were subjected to PCR using
primers specific for the conserved flanking regions of loop 4 hgbAI and hgbAII.
The upstream and downstream hgbA primers (5-CTAACCCTTCTGGGCTAT
AC-3 and 5-GCTAGGTAAATACACACGGC-3, respectively) generated a
PCR product of approximately 350 bp from either strain. The PCR steps used for
amplification are as follows: an initial 5-min 94°C denaturing step was followed
by 30 cycles of 1 min of denaturation at 94°C, annealing for 30 s at 45°C, and
extension for 30 s at 72°C. A final polishing step for 5 min at 72°C was used prior
to completion. PureTaq Ready-To-Go PCR beads (GE Healthcare, Bucking-
hamshire, United Kingdom) were used according to the manufacturer’s instruc-
tions. Ten picomoles of PCR primers were used, along with 1 l of cells (OD600
of 0.2 in 50 l of water) as template. PCR products were purified using a Qiagen
PCR purification kit (Qiagen, Valencia, CA) and sequenced using the upstream
PCR primer at the UNC Genome Analysis Facility.
Whole-cell immunoprecipitation. H. ducreyi strains were grown overnight in
heme-limiting conditions to induce the expression of HgbA at 34.5°C in 50-ml
broth cultures of GC broth, 5% Fetalplex, 1% GGC in the presence of 5% CO2
(17). Whole-cell immunoprecipitation was performed as previously described
with the following modifications (26, 44, 60): H. ducreyi cultures were centrifuged
and the pellets suspended to an OD600 of 1.0 (approximately 5  108 CFU/ml)
in GC broth. Ten microliters of serum was added to 1 ml of the bacterial
suspension and rocked at room temperature for 20 min. Bacterial cells were
centrifuged, and the supernatant discarded to remove unbound antibody and
serum components. The washed cell pellet was resuspended in 100 l PBS, and
1 ml of 2% Zwittergent 3-14 (ZW 3-14) (Calbiochem) in TEN buffer (50 mM
Tris-HCl, 5 mM EDTA, 150 mM NaCl, pH 8.0) was added to solubilize proteins.
After incubation at 37°C with agitation for 1 h, the tube was centrifuged for 10
min at 14,000 rpm to remove insoluble debris. The supernatant containing ZW
3-14-soluble total cellular proteins and antigen/antibody complexes was moved to
a new tube containing 25 l of a 50% slurry of protein A/G agarose beads
(ExAlpha Biologicals, Shirley, MA). The tubes were incubated for 2 h or over-
night to allow binding of antigen/antibody complexes to the protein A/G beads.
The tubes were centrifuged and washed thrice using 0.5% ZW 3-14 in TEN. The
agarose pellet was then resuspended in 1 ml TEN, moved to a fresh tube, and
centrifuged, and the supernatant discarded. Forty microliters of Laemmli sample
buffer lacking any reducing agents was added to the washed agarose, the tubes
boiled for 5 min at 95°C, and 20 l of the mixture subjected to SDS-PAGE and
Coomassie staining.
Western blotting. Samples were subjected to SDS-PAGE and transferred onto
nitrocellulose, which was blocked in 0.5% Tween 20–PBS for 1 h. Rabbit anti-
N-terminal HgbA peptide antiserum diluted at 1:500 was used as the primary
antibody (17). The sequence of the peptide used to generate the anti-N-terminal
antiserum is identical in both classes of HgbA proteins and should therefore bind
HgbAI and HgbAII equally. Alkaline phosphatase-conjugated goat anti-rabbit
IgG (Sigma, St. Louis, MO) diluted at 1:20,000 was used as the secondary
antibody. Protein bands were visualized using Lumi-Phos (Thermo Scientific,
Rockford, IL).
Statistics. Statistical analyses were performed using the SigmaStat program
(version 3.5; Systat Software, CA). A Mann-Whitney rank sum test was per-
formed for the nonparametric data obtained in the ELISAs and for histology
scoring. Fisher’s exact test was used to compare bacterial recovery at the animal
and lesion levels (Table 1).
RESULTS
Construction of H. ducreyi strain 35000HP expressing the
hgbA gene from class II strain DMC111. In preliminary swine
challenge experiments using H. ducreyi strains other than
35000HP, all tested strains from either class were less infec-
tious than strain 35000HP (data not shown). Furthermore, H.
ducreyi wild-type strain 35000HP grows faster than the class II
strains. Therefore, because of these and other phenotypic dif-
ferences between classes of H. ducreyi strains, we engineered
an isogenic 35000HP strain expressing the class II hgbA gene
from strain DMC111 (35000HPhgbAII) to determine if the
nHgbAI vaccine would be protective against a class II HgbA-
expressing strain. In preliminary pig virulence studies, lesions
produced by strain 35000HPhgbAII were indistinguishable
from lesions caused by the 35000HP parent strain and the
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HgbAII protein was expressed at the same level as HgbAI in
the 35000HP background (data not shown).
The nHgbAI/MPL vaccine reduced lesion severity after a
homologous challenge. Pigs were immunized and challenged as
described in Materials and Methods using a protocol identical
to that of the previous HgbA vaccine study (1). The following
parameters were analyzed: pig ear lesions were examined at
both the macroscopic and microscopic levels; recovery of H.
ducreyi was determined; and antisera from nHgbAI-immunized
animals were subjected to several in vitro immunological as-
says, including different types of ELISAs, to measure antibody
activity to nHgbAI, binding to whole cells of H. ducreyi, and the
ability of IgGs from immunized animals to block Hb binding to
both nHgbAI and nHgbAII. The bactericidal activity of anti-
nHgbAI antisera was measured using a classic bactericidal
assay.
Figure 1A shows representative photographs of lesions from
pigs challenged with both strains of H. ducreyi taken immedi-
ately prior to biopsy. In animals immunized with nHgbAI,
inoculation with homologous strain 35000HPhgbAI produced
small lesions (Fig. 1A1), and in some cases, lesions were un-
detectable, save for puncture wounds from the applicator de-
vice. In contrast, infection of mock-immunized animals with both
strains of H. ducreyi (Fig. 1A2 and 4) produced raised, visible
lesions, much larger than those found in nHgbAI-immunized an-
imals challenged with strain 35000HPhgbAI, indicating that both
challenge strains are virulent in the experimental swine model of
chancroid. The lesions of nHgbAI-immunized animals challenged
TABLE 1. Recovery of H. ducreyi 35000HPhgbAI and 35000HPhgbAII from biopsy specimens
HgbA
class Expt
Mock immunization HgbA immunization
Pig
No. of H. ducreyi-positive
specimens/total no. of specimens
Pig
No. of H. ducreyi-positive









I 1 1 2/3 3/3 3 0/4 NDa
2 3/3 2/3 4 0/4 ND
2 5 4/4 2/4 7 0/4 0/4
6 4/4 2/4 8 0/4 0/4
Total 13/14b 9/14d 0/16b 0/8d
II 1 1 2/3 3/3 3 3/4 ND
2 3/3 2/3 4 1/4 ND
2 5 4/4 4/4 7 3/4 4/4
6 1/4 1/4 8 3/4 1/4
Total 10/14c 10/14e 10/16c 5/8e
a ND, not determined.
b P  0.001, Fisher’s exact test.
c P  0.709, Fisher’s exact test.
d P  0.006, Fisher’s exact test.
e P  1.000, Fisher’s exact test.
FIG. 1. nHgbAI/MPL vaccine reduces lesion severity of experimental chancroid at the macroscopic and microscopic levels. (A) Photographs of pig
ear lesions. Pigs were either mock immunized with MPL adjuvant only (2 and 4) or immunized with nHgbAI/MPL (1 and 3) and challenged with either
H. ducreyi strain 35000HPhgbAI (1 and 2) or 35000HPhgbAII (3 and 4). Photos were taken 1 week after challenge and immediately prior to biopsy.
(B) H&E-stained biopsy sections from pig ears 1 week after infection. Pigs were either mock immunized with MPL adjuvant only (6 and 8) or immunized
with nHgbAI/MPL (5 and 7) and challenged with either H. ducreyi strain 35000HPhgbAI (5 and 6) or 35000HPhgbAII (7 and 8) (magnification, 50).
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with heterologous strain 35000HPhgbAII (Fig. 1A3) appeared
similar to those from mock-immunized pigs.
Figure 1B shows representative histological sections of lesion
biopsy specimens stained with H&E. In nHgbAI-immunized an-
imals challenged with homologous strain 35000HPhgbAI (Fig.
1B5), a low level of inflammatory cell infiltrate was present in
the lesions, and the basement membrane was intact, resem-
bling healthy sections (52). In mock-immunized animals chal-
lenged with either strain (Fig. 1B6 and 8), there was a dense
infiltrate of neutrophils and the epidermal-dermal border was
completely destroyed, which left the dermis exposed, similar to
previous results (1) and comparable to natural and experimen-
tal infection in humans (34, 56). In the nHgbAI-immunized
heterologous challenge group (Fig. 1B7), the lesions appeared
to be similar to those of mock-immunized animals.
We used a previously described grading system based on a
1-to-5 range (for lesion scores, see Materials and Methods) to
judge the severity of lesions in each group of animals (52). The
mean lesion grade of mock-immunized animals challenged with
the homologous strain was 4.0  0.76, whereas the nHgbAI-
immunized group challenged with the same strain had a score
of 2.6  0.78 (P  0.002). The mean lesion grade for the
control group challenged with the heterologous strain was
4.1  1.3, compared to a score of 3.7  1.3 for nHgbAI-
immunized animals (P  0.442).
Viable H. ducreyi cells were not recovered from lesions of
nHgbAI-immunized pigs challenged with a homologous H.
ducreyi strain. The recovery of viable H. ducreyi cells from
biopsy specimens is shown in Table 1. At both challenge
inocula (104 and 103 CFU), no H. ducreyi cells were isolated
from nHgbAI-immunized animals challenged with homolo-
gous strain 35000HPhgbAI, whereas all mock-immunized an-
imals yielded viable H. ducreyi (P  0.001). In heterologous
challenge experiments, all pigs, whether nHgbAI or mock
immunized, yielded strain 35000HPhgbAII (P  1.000).
Analysis of bacterial recovery at the lesion level revealed strik-
ing differences between nHgbAI- and mock-immunized animals
infected with the homologous H. ducreyi strain. In the control
group, 13 of 14 lesions yielded H. ducreyi strain 35000HPhgbAI at
an inoculum of 104 CFU. In the nHgbAI-immunized group, 0 of
16 lesions yielded H. ducreyi (P  0.001). At the lower dilution
(103 CFU), 9 of 14 lesions in mock-immunized animals yielded H.
ducreyi strain 35000HPhgbAI, whereas 0 of 8 lesions yielded H.
ducreyi strain 35000HPhgbAI in nHgbAI-immunized animals (P 
0.006). Thus, the nHgbAI vaccine provided protection against a
bacterial challenge of at least 10 times the minimum infectious
dose. In heterologous challenge experiments, 10 of 14 lesions in
the control group yielded H. ducreyi strain 35000HPhgbAII, com-
pared to 10 of 16 lesions from the nHgbAI-immunized group at a
104 CFU inoculum (P  0.709). Therefore, based on macroscopic
examination, histological sections, and recovery of H. ducreyi cells,
there was homologous protection against strain 35000HPhgbAI
but no protection against the genetically engineered heterologous
strain 35000HPhgbAII by the nHgbAI vaccine.
The activity of the antiserum from nHgbAI/MPL-immunized
animals was lower than the activity of antiserum of nHgbAI/
Freund’s-immunized pigs. We analyzed the humoral immune
response of nHgbAI-immunized animals in a number of in vitro
assays. An ELISA was performed to compare the antibody
activity developed in response to our current MPL adjuvant
HgbA vaccine to that of antiserum generated from the previ-
ous study using Freund’s adjuvant (Fig. 2). The Freund’s an-
tiserum activity was approximately 7-fold higher than the MPL
antiserum activity prior to the second immunization (P 
0.029) and approximately 2 to 3 times higher than the MPL
activity after the third immunization (prior to infection) (P 
0.057). Of note, one of the four pigs immunized with nHgbAI/
MPL (pig 4M) showed ELISA activity twice as high as that found
for the other three MPL-immunized pigs after the third immuni-
zation, indicating that different animals can respond differently to
the vaccine preparation. Preimmune and mock-immune pig sera
were free of anti-nHgbAI antibodies (data not shown).
Two different assays were employed to determine whether
antisera from nHgbAI/MPL-immunized pigs recognized sur-
face-exposed epitopes of HgbA in the context of whole cells of
H. ducreyi. The first technique, a whole-cell binding ELISA, mea-
sured the relative amounts of antibodies bound to the surface of
different H. ducreyi strains expressing either class I (wild-type
strain 35000HPhgbAI) or class II (strain 35000HPhgbAII) HgbA
or expressing class II HgbA in the native class II H. ducreyi
background (wild-type strain DMC111), as detected by a sec-
ondary antibody conjugate (Fig. 3) and compared to an
H. ducreyi strain that does not express HgbA (strain
35000HPhgbA). Antisera from all four nHgbAI/MPL-immu-
nized pigs and pooled anti-nHgbAI/Freund’s antisera showed
greater reactivity with strain 35000HPhgbAI than with strains
35000HPhgbAII, 35000HPhgbA, or DMC111 (Fig. 3). As was
observed in the solid-phase ELISA, there was also a statisti-
cally significant difference between the reactivity of pooled
nHgbAI/Freund’s antiserum and all four nHgbAI/MPL anti-
sera with strain 35000HPhgbAI (P values range from  0.001 to
0.005) (Fig. 3). Antisera taken from mock-immunized pigs and
prebleeds from nHgbAI/MPL-immunized pigs reacted poorly
with all strains of H. ducreyi tested (data not shown).
The second method used to examine the interaction between
FIG. 2. The activity of the nHgbAI/MPL antisera is lower than that
of the antisera from nHgbAI/Freund’s-immunized animals. Sera were
collected preimmunization (prebleed), before the second immuniza-
tion, and prior to challenge infection (three weeks after the third
immunization). Data are expressed as OD405 readings and given as
median  variance. Solid lines represent data from each pig immu-
nized with nHgbAI/Freund’s adjuvant (1F, 4F, 5F, and 6F) (1),
whereas dotted lines represent data from pigs immunized with nHg-
bAI/MPL adjuvant (3M, 4M, 7M, and 8M). ELISA data for week 6
(prior to 3rd immunization) are not shown due to an incomplete
data set for nHgbAI/Freund’s antiserum samples. P values comparing
anti-nHgbAI antibodies using Freund’s and MPL adjuvants after one
and after three immunizations (just prior to challenge) were 0.029 and
0.057, respectively, and were determined using the Mann-Whitney
rank sum test (n  3).
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anti-nHgbAI and surface-exposed epitopes on H. ducreyi whole
cells was an immunoprecipitation assay. Immunoprecipitates
were analyzed by Coomassie blue staining (Fig. 4A) and Western
blotting (Fig. 4B). Pooled anti-nHgbAI/MPL antisera precipi-
tated nHgbAI from H. ducreyi strain 35000HPhgbAI but with less
reactivity than with pooled antisera from pigs immunized with
nHgbAI/Freund’s (Fig. 4A1 and B1). Neither antibody prepara-
tion precipitated nHgbAII in a 35000HP background (Fig. 4A2
and B2). Only pooled anti-nHgbAI/Freund’s was able to immu-
noprecipitate nHgbAII from the wild-type strain DMC111 (Fig.
4A3 and B3).
Antiserum elicited by the nHgbAI/MPL vaccine partially
inhibited the binding of DIG-Hb to nHgbA. We examined the
ability of purified anti-nHgbAI IgG to block the binding of Hb
to immobilized nHgbAI or nHgbAII in an ELISA format (1).
Pooled IgG purified from serum of nHgbAI/Freund’s-immu-
nized pigs (1) blocked 59% of DIG-Hb/nHgbAI binding, while
pooled IgG purified from nHgbAI/MPL-immunized pigs
blocked 48% of binding (P  0.180) (Fig. 5). There was a
significant difference between IgGs purified from nHgbAI/
Freund’s-immunized (38.1% inhibition) and nHgbAI/MPL-im-
munized pigs (20.6% inhibition) (P  0.002) (Fig. 5) in block-
ing Hb/nHgbAII interactions. IgG purified from pooled sera of
mock-immunized pigs failed to interfere with the binding of
Hb to either nHgbAI or nHgbAII (data not shown).
Antisera from nHgbAI/MPL pigs did not exhibit bacteri-
cidal activity. We performed immune bactericidal assays using
purified IgG from nHgbAI/MPL-immunized pigs as previously
described (1, 18). We were unable to demonstrate bactericidal
killing in the presence of human complement using either H.
ducreyi strain as a target (data not shown).
DISCUSSION
Administering the nHgbAI vaccine with an adjuvant ap-
proved for use in humans was as effective as using Freund’s
adjuvant. This study is similar to a previous vaccine study
conducted in our laboratory, which demonstrated complete
protection using purified nHgbAI as immunogen (1). In the
previous study, we used Freund’s adjuvant, while MPL was
used as adjuvant in the present study. Monophosphoryl lipid A
FIG. 3. nHgbAI/MPL antisera bind HgbAI but not HgbAII in the
context of whole H. ducreyi cells. Antisera from individual pigs (pigs 3,
4, 7, and 8), obtained after three immunizations with nHgbAI/MPL,
and pooled antiserum from pigs immunized with nHgbAI/Freund’s
(Fp; obtained from a previous study) (1) were tested for binding to
whole cells of H. ducreyi strains 35000HPhgbAI, 35000HPhgbAII,
35000HPhgbA, and DMC111. The antisera used in these assays were
from preinfection bleeds. Experiments were performed in triplicate on
at least three different days. Data are expressed as relative light units
and given as median  variance. A P value of 0.005 was found for the
difference between the binding of nHgbAI/MPL and nHgbAI/Freund’s
antisera to whole cells of H. ducreyi strain 35000HPhgbAI (Mann-
Whitney rank sum test).
FIG. 4. nHgbAI/MPL antiserum immunoprecipitates only HgbAI
from whole cells of H. ducreyi. The ability of anti-nHgbAI antisera to
immunoprecipitate HgbA from different H. ducreyi strains is shown in a
Coomassie blue-stained 10% SDS–PAGE gel (A) and a Western blot
probed with an antiserum to full-length rHgbAI (19) (B). The H. ducreyi
strains used in these immunoprecipitation assays were 35000HPhgbAI (1),
35000HPhgbAII (2), and DMC111 (3). Antisera used in these experiments
were either pooled anti-nHgbAI/Freund’s (Fp) purified from antisera
obtained in a previous study (1) or pooled anti-nHgbAI/MPL (Mp). Mo-
lecular size markers are shown in kilodaltons.
FIG. 5. IgGs from nHgbAI/MPL-immunized animals partially in-
hibit Hb binding to nHgbA. The ability of pooled IgGs from pigs
immunized with either nHgbAI/MPL or nHgbAI/Freund’s to inhibit
the binding of Hb to immobilized nHgbAI or nHgbAII was measured.
P values comparing the ability of anti-nHgbAI IgG to block Hb binding
to nHgbAI and nHgbAII were determined using the Mann-Whitney
rank sum test. Pooled nHgbAI/Freund’s IgG was purified from antisera
obtained in a previous study (1) (n  3).
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(MPL) is a detoxified lipopolysaccharide analog isolated from
Salmonella enterica serovar Minnesota R595. The structure,
mechanism of action, and immunologic responses to MPL
have been the subjects of intense investigation for many de-
cades (11), and the safety of MPL has been extensively docu-
mented (5, 65). MPL has been successfully utilized as an ad-
juvant in numerous human vaccines, including vaccines for
human papillomavirus 16/18 (HPV) (27, 28, 46), hepatitis B
virus (HBV) (36, 61), and herpes simplex virus (HSV) (57). In
these trials, MPL was used in combination with alum in the
GSK proprietary AS04 adjuvant system (23). MPL has also
been examined as an adjuvant in vaccines against malaria (24,
30, 59), leishmania (9), anthrax (32), Epstein-Barr virus (EBV)
(54), and HIV (39, 43) and against allergies to house dust mites
(6), ragweed pollen (7), and grass pollen (16). All of these
studies showed that MPL is a successful and safe adjuvant.
The nHgbAI vaccine administered with MPL protected only
against a homologous H. ducreyi strain. The current study
advances the findings from the original nHgbAI vaccine study
in that we examined the ability of this vaccine to protect against
strain 35000HP expressing a (heterologous) class II HgbA pro-
tein (HgbAII). In alignments of HgbA from 10 strains of H.
ducreyi, HgbA was highly conserved, showing 95% identity
between strain classes (67). Based on this high degree of
identity, we anticipated that nHgbAI would provide cross-
protection against strains expressing HgbA from either class
of H. ducreyi strains. Surprisingly, this is not what we ob-
served. Immunization with the nHgbAI/MPL vaccine offered
full protection to pigs when challenged with H. ducreyi strain
35000HPhgbAI (homologous), but not from a challenge with
H. ducreyi strain 35000HPhgbAII (heterologous). Since these
are isogenic strains, except for the HgbA protein (HgbAI
versus HgbAII), two conclusions can be drawn from the
results: (i) slight dissimilarities in the amino acid sequence
between these 2 proteins are responsible for the difference
in protection, and (ii) the observed protection cannot be the
result of a protective response elicited by minor antigens
contaminating the vaccine preparation.
In another of our previous studies, we found that loop 4 of
HgbA is surface exposed and the largest, most immunodomi-
nant and variable loop among the 11 putatively exposed loops
of HgbA (44). Including the highly conserved membrane-span-
ning segments, loops 4 of HgbA proteins are 91% identical
between strains (16 of 186 amino acids are different). These
results suggest that at least part of the protective response
against HgbAI lies in exposed epitopes from loop 4. Such
divergence between strains in protective epitopes of surface-
exposed outer membrane proteins has been shown in the de-
velopment of gonococcal and meningococcal protein vaccines
(15, 42, 64) and resulted in the requirement for multivalent
vaccines in the latter.
Because preliminary experiments showed that wild-type
class II strains were either weakly or noninfectious in the swine
model (data not shown), an H. ducreyi class I strain expressing
a class II HgbA protein was constructed in the current study in
order to determine the possibility of heterologous protection.
However, the use of an isogenic class II construct has certain
limitations. Class II strains typically grow more slowly than
class I strains, which may explain why they were less infectious
in the swine model. Moreover, class II strains have a truncated
LOS compared to that of class I strains (50, 53, 67), and it is
possible that HgbAII may be more exposed in a truncated LOS
background. In data not presented here, anti-HgbA monoclo-
nal antibody 1.51 binds poorly to whole cells of wild-type
35000HPhgbAI but binds a 35000HP gmhA mutant (an isogenic
mutant with a short LOS) (8) and two of four class II strains
containing truncated LOS, including strain DMC111 (data not
shown). These data suggest that the presence of a longer LOS
molecule is responsible for the lack of monoclonal antibody
1.51 binding to HgbA on the surface of H. ducreyi. As shown by
the results in Fig. 4, polyclonal anti-nHgbAI antibodies bound
better to strain DMC111 than to strain 35000HPhgbAII, con-
sistent with this notion. Thus, if additional HgbA epitopes are
exposed in the context of a class II LOS, then it is possible that
the nHgbAI vaccine might offer some cross-protection for wild-
type class II H. ducreyi strains.
Despite activity lower than that of antiserum from anti-
nHgbAI/Freund’s immunization, antiserum from animals im-
munized with the nHgbAI/MPL vaccine partially blocked
DIG-Hb binding to HgbA. The ELISA activity of antiserum
from HgbAI/MPL-immunized pigs to nHgbAI was lower than
the activity of antiserum from our earlier study using Freund’s
adjuvant after the first and third immunizations. These results
are consistent with the results of two other immunization stud-
ies using other protein antigens in rabbits, which showed
higher ELISA activity obtained using Freund’s adjuvant (33,
41). We attempted to compare the antibody response of
nHgbAI/MPL antiserum to immobilized nHgbAII in an ELISA
format to determine if this might correlate with protection.
However, the two HgbA proteins did not appear to bind the
ELISA plates equally or may not have been equally in native
conformation, either of which may have skewed the results.
Variability in binding and folding of the different classes of
HgbA proteins also prevented us from making valid conclu-
sions about the results obtained in the ELISA measuring
blocking of Hb binding (Fig. 5), even though some compari-
sons were statistically significant. Further work is necessary to
elucidate the causes of the different binding capabilities of
classes of HgbA proteins.
Instead of making comparisons of antiserum binding to pu-
rified protein, we compared the binding of nHgbAI/MPL an-
tisera to whole cells of the isogenic pair of 35000HP strains. As
predicted, the homologous strain bound more antibodies than
the heterologous strain in both whole-cell ELISA and the
immunoprecipitation assay (Fig. 3 and 4). Similar to the activ-
ity measured by ELISA, the whole-cell antibody binding activ-
ity from the previous nHgbAI/Freund’s immunization study
was higher than the activity from the present nHgbAI/MPL
study.
The ability of antibodies to block Hb binding to immobilized
nHgbAI and nHgbAII was measured using an ELISA-based
assay. Antibodies from both MPL and Freund’s adjuvant
groups modestly blocked Hb binding to either class of HgbA
protein (Fig. 5). Despite significantly higher ELISA activity
with Freund’s antiserum, there was no significant difference in
the ability of either IgG pool to inhibit Hb binding to homol-
ogous HgbAI. However, Freund’s pooled IgG significantly in-
hibited the binding of Hb to heterologous HgbAII compared to
the inhibition by MPL pooled IgG.
The lack of bactericidal and opsonophagocytic killing of H.
VOL. 78, 2010 H. DUCREYI HgbA VACCINE WITH MPL ADJUVANT 3769
ducreyi is well documented in the literature (2, 22, 31, 37, 45,
63, 68). In this study, bactericidal activity was not observed
using antisera from nHgbAI/MPL-immunized pigs. This dif-
fered from the results of a previous study that showed modest
bactericidal activity using antiserum from nHgbAI/Freund’s-
immunized pigs (1). The lack of bactericidal activity using
nHgbAI/MPL antisera may be due to lower antibody titers,
lower antibody affinity, or inability to fix complement.
We previously studied opsonophagocytosis by nHgbAI/
Freund’s pooled antisera. In a luminol-enhanced chemilumi-
nescence assay, human neutrophils were not significantly stim-
ulated in the presence of nHgbAI/Freund’s antiserum and
complement, whereas controls stimulated neutrophils (data
not shown). Furthermore, human neutrophils failed to kill H.
ducreyi cells opsonized with nHgbAI/Freund’s antiserum and
complement, while control bacteria were killed (data not
shown). Since nHgbAI/Freund’s antiserum, which has a higher
activity than nHgbAI/MPL antiserum, did not exhibit any
bactericidal activity, we did not test the opsonic activity of
nHgbAI/MPL antiserum obtained in the current study.
Future studies. Anti-nHgbAI antibodies bound better to
class I-specific epitopes and failed to protect against a heter-
ologous challenge, which suggests that the protective epitopes
lie in the divergent central domain of HgbA. Studies are under
way to determine whether a vaccine containing the central
domain of HgbA (loops 4 through 7) is protective for class I
strains.
The mechanism of protection of the HgbA vaccine (cellular
versus humoral) is not known. However, the results of a pre-
vious study using passively transferred serum from thrice-in-
fected pigs suggested that the humoral response was sufficient
to protect from an H. ducreyi challenge (13). Studies are under
way in our laboratory to determine whether protection using
passively transferred serum from nHgbAI-immunized pigs is
sufficient to provide protection.
Based on our results, it remains unclear whether a single
HgbA protein will protect against both classes of H. ducreyi,
and it is possible that a bivalent vaccine might be needed.
While anti-nHgbAI antibodies did not bind well to class II
HgbA in the genetically engineered 35000HP background, they
bound moderately well to class II HgbA in the wild-type class
II (DMC111) background, possibly due to differences in LOS
or other antigens. Thus, based on our previous (1), present,
and a third study under way (unpublished data), binding to
whole cells and blocking Hb binding to HgbA are the two in
vitro assays that correlate with the protection of the nHgbAI
vaccine.
The immune response to nHgbAI/MPL was relatively mod-
est, similar to the results of other studies using different anti-
gens. Newer vaccines using MPL have overcome this problem
by including alum in the vaccine mixtures with MPL (termed
AS04), and we will examine this in our system. Despite these
limitations, we have proof of concept that nHgbAI in conjunc-
tion with an adjuvant approved for use in humans can provide
complete homologous protection in a highly relevant animal
model, paving the way toward phase I clinical trials.
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